Why This Matters: Drug pricing policies can shape how quickly Canadians gain access to new medicines and future innovation.
In this opinion piece from the Financial Post, Nigel Rawson and Andrew Darke argue that Canada’s low prices for patented drugs may contribute to less and slower access to innovative medicines. The authors suggest new U.S. drug pricing policies could pressure Canada to rethink how it values pharmaceutical innovation and patient access.